The cost-effectiveness of human papillomavirus vaccine catch-up programs for women

Journal of Infectious Diseases

Volumn 211, Issue 2, 2015, Pages 172-174

  Chesson, Harrell W ^a   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

cost effectiveness analysis; HPV; human papillomavirus; models; vaccine

Indexed keywords

WART VIRUS VACCINE;

AGE; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INFECTION PREVENTION; INNATE IMMUNITY; LONG TERM CARE; NOTE; PAPILLOMAVIRUS INFECTION; QUALITY OF LIFE; SEX DIFFERENCE; SHORT COURSE THERAPY; UTERINE CERVIX CANCER; VACCINATION; ECONOMICS; FEMALE; MALE; PAPILLOMAVIRUS INFECTIONS;

FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84922447105     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu414     Document Type: Note

References (18)

1. Brisson M, Van De Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12:343-51.
2. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012; 30(suppl 5):F157-67.
3. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29:8443-50.
4. Burger EA, Sy S, Nygard M, Kristiansen IS, Kim JJ. Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway. J Infect Dis 2015; 211:206-15.
5. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32.
6. Kim JJ, Kobus KE, Diaz M, O'Shea M, Van MH, Goldie SJ. Exploring the costeffectiveness of HPV vaccination in Vietnam: Insights for evidence-based cervical cancer prevention policy. Vaccine 2008; 26:4015-24.
7. Burger EA, Sy S, Nygard M, Kristiansen IS, Kim JJ. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include preadolescent boys. PLoS One 2014; 9:e89974.
8. Turner HC, Baussano I, Garnett GP. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PLoS One 2013; 8: e75552.
9. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13:28-41.
10. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769.
11. Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013; 53:679-82.
12. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw C. Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sex Transm Infect 2009; 85:499-502.
13. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-51.
14. Chesson H, Markowitz L. The costeffectiveness of quadrivalent human papillomavirus vaccination of females over age 12 years in the United States. In: Alary M, ed. Proceedings of the 19th Conference of the International Society for STD Research (Quebec City, Canada), 10-13 July 2011. Bologna, Italy: Medimond, 2011:19-22. In Alary M, e.d.
15. Castellsague X, Naud P, Chow SN, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis 2014; 210: 517-34.
16. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24(suppl 3): S178-86.
17. Van De Velde N, BrissonM, BoilyMC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative modelbased analysis. Vaccine 2010; 28:5473-84.
18. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. Vaccine 2013; 31:3899-905.